Sector News

AstraZeneca oncology head jumps ship to become Innate CEO

December 20, 2016
Life sciences

AstraZeneca is losing its head of oncology, Mondher Mahjoubi, who is departing to lead French biotech company Innate Pharma.

Innate said on Monday that Mahjoubi would take over as chief executive on Dec. 30, replacing Herve Brailly who is moving on to become chairman of the supervisory board.

The loss of Mahjoubi is a setback for AstraZeneca, given the British drugmaker’s focus on new cancer treatments. Mahjoubi previously worked at Roche’s (ROG.S) Genentech unit before joining AstraZeneca, where he has helped lead oncology strategy.

His departure comes ahead of key clinical trial read-outs for the company’s experimental immunotherapy drugs.

AstraZeneca said Mahjoubi’s successor would be announced shortly.

For Mahjoubi, the move to Innate offers the opportunity to run a company that specialises in immuno-oncology, which is now transforming the fight against several different types of cancer.

Innate said he would be paid a base salary of 470,000 euros ($490,000). He will also get free shares in the company and be eligible for pay and share bonuses, if certain targets were met.

Shares in Innate were 4 percent higher by 1230 GMT while AstraZeneca slipped 1.4 percent.

By Ben Hirschler

Source: Reuters

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend